No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?

Ann Oncol. 2017 Aug 1;28(8):2030-2031. doi: 10.1093/annonc/mdx231.

Authors

Y Sunakawa¹, A Tsuji², M Fujii³, W Ichikawa⁴

Affiliations

¹ Division of Medical Oncology, Showa University Northern Yokohama Hospital, Tsuzuki-ku, Yokohama, Kanagawa.
² Department of Clinical Oncology, Kagawa University Faculty of Medicine Cancer Center, Kagawa University Hospital, Miki-cho, Kita-gun, Kagawa.
³ Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo.
⁴ Division of Medical Oncology, Showa University Fujigaoka Hospital, Aoba-ku, Yokohama, Kanagawa, Japan.

PMID: 28475674
DOI: 10.1093/annonc/mdx231

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / immunology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cetuximab / administration & dosage
Cetuximab / immunology
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / enzymology
Colorectal Neoplasms / immunology
Colorectal Neoplasms / pathology*
ErbB Receptors / immunology
Humans
Neoplasm Metastasis

Substances

Antineoplastic Agents, Immunological
EGFR protein, human
ErbB Receptors
Cetuximab